title: Prospective economic evaluation accompanying a trial of GM-CSF/IL-3 in patients undergoing autologous bone marrow transplantation for Hodgkin's and non-Hodgkin's lymphoma. IL-3 BMT Study Team.
abstract: Our objective was to assess the economic impact of a new cytokine therapy that was being compared to standard therapy as supportive care in patients receiving autologous bone marrow transplantation for treatment of lymphoma. We performed an economic study accompanying a multicenter, randomized, controlled clinical trial in academic medical centers. One hundred and fifteen patients consented to participate in a parallel economic study of a randomized controlled trial of sequential IL-3 followed by GM-CSF vs GM-CSF alone after autologous bone marrow transplantation. We measured costs and quality-adjusted survival over a 13-month follow-up period. For the 13-month study period, the total cost estimates were $79892 (95% CI $69343 to $90544) for patients receiving GM-CSF alone and $89651 (95% CI $79769 to $102114) for patients receiving IL-3/GM-CSF. The difference was not statistically significant. During the 13-month study period, the total number of quality-adjusted life-months in the GM-CSF arm was 6.67 (95% CI 5.75 to 7.56) months, while the total number of quality-adjusted life-months in the IL-3 arm was 6.26 (95% CI 5.34 to 7.15) months. The difference in quality-adjusted life-months between the two treatment arms was not statistically significant. We conclude that economic analysis of a phase III clinical trial of IL-3/GM-CSF compared with GM-CSF alone showed no significant effect of IL-3 on the costs of care for patients undergoing bone marrow transplantation for a period of up to 13 months after the procedure. This study demonstrates the feasibility of prospective economic evaluation within phase III trials of new cancer therapies. Data from this type of economic protocol could be used to help physicians, patients and managed care organizations understand the effect of new treatments from both a clinical and an economic perspective.
authors.affiliation: Clinical Economics Research Unit, Georgetown University Medical Center, Washington, DC 20007, USA.
authors.forename: K A
authors.initials: KA
authors.lastname: Schulman
authors.forename: D
authors.initials: D
authors.lastname: Dorsainvil
authors.forename: K R
authors.initials: KR
authors.lastname: Yabroff
authors.forename: J
authors.initials: J
authors.lastname: DiCesare
authors.forename: J
authors.initials: J
authors.lastname: Felser
authors.forename: J M
authors.initials: JM
authors.lastname: Eisenberg
authors.forename: H A
authors.initials: HA
authors.lastname: Glick
mesh_terms: D016026:Bone Marrow Transplantation / Q000191:economics; D005260:Female; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000191:economics* / Q000627:therapeutic use*; D006689:Hodgkin Disease / Q000628:therapy*; D006801:Humans; D007377:Interleukin-3 / Q000191:economics* / Q000627:therapeutic use*; D008228:Lymphoma, Non-Hodgkin / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009504:Neutrophils / Q000637:transplantation; D011446:Prospective Studies; D011788:Quality of Life; D016019:Survival Analysis; D013997:Time Factors; D014182:Transplantation, Autologous
chemical_list: D007377:Interleukin-3; D016178:Granulocyte-Macrophage Colony-Stimulating Factor